Crypto trading platform FalconX is planning to acquire ETF asset manager firm 21Shares in one of the largest mergers in the cryptocurrency financial industry this year. According to a report by the Wall Street Journal, the digital asset trading platform…Crypto trading platform FalconX is planning to acquire ETF asset manager firm 21Shares in one of the largest mergers in the cryptocurrency financial industry this year. According to a report by the Wall Street Journal, the digital asset trading platform…

FalconX to buy out crypto asset ETF firm 21Shares

Crypto trading platform FalconX is planning to acquire ETF asset manager firm 21Shares in one of the largest mergers in the cryptocurrency financial industry this year.

Summary
  • FalconX will acquire 21Shares, one of the largest crypto-focused asset managers, in an undisclosed deal that would merge the two companies into one.
  • The deal comes amid a surge in crypto ETF activity following the SEC’s shorter approval timeline, with 155 new filings across 35 digital assets and billions flowing into products like the ARK 21Shares Bitcoin ETF.

According to a report by the Wall Street Journal, the digital asset trading platform FalconX is set to acquire one of the largest managers of exchange-traded funds in a landmark deal. Executives from both companies confirmed that the merger would establish a combined company that would focus on developing crypto funds centered around derivatives and structured products.

The amount of funds used to acquire 21Shares was not disclosed by either company, but it was revealed that the deal was financed through a mix of cash and equity.

The acquisition comes at a time when crypto ETFs are picking up speed after the Securities and Exchange Commission significantly shortened the approval timeline for ETFs from 270 days to just 75 days. The decision gave way to a rise in crypto-backed ETF applications, with asset managers scrambling to apply for more crypto ETFs in hopes of bringing them into the market.

According to data from Solid Intel, the number of crypto ETF filings has surged to 155 within the span of a year, spanning across 35 digital assets.

Established in 2018, 21Shares has grown into one of the largest crypto-focused asset management firms, handling more than $11 billion in assets across 55 listed exchange-traded products as of September 2025. 21Shares is well regarded for launching one of the first spot Bitcoin ETFs (BTC) in the U.S in partnership with Cathie Wood’s ARK Investment Management, ARK 21Shares Bitcoin ETF.

At press time, ARK 21Shares Bitcoin ETF has seen inflows amounting to $162.85 million within the past 24 hours, trailing just behind BlackRock’s IBIT with inflows of $210.9 million. The product’s cumulative net inflow has increased to $2.22 billion as of Oct. 22.

Overall, the U.S BTC Spot ETF market has seen a total of $477.19 million inflows, with Ark & 21 Shares’ Bitcoin ETF being in the top five largest contributors.

FalconX expands into structured products through 21Shares

As the number of crypto ETFs increases, so does investor appetite for more structured crypto products. The crypto ETF market started off with funds backed mostly by Bitcoin and Ethereum (ETH); now it has expanded with the launch of ETFs that invest in smaller altcoins.

FalconX co-founder Raghu Yarlagadda said that through the merger, the combined company will be able to bring products into the market at a faster pace.

“Bitcoin flows are now happening through what we call traditional wrappers, and that’s a fundamental shift in market structure,” said Yarlagadda in a statement to the Wall Street Journal.

FalconX started primarily as a prime brokerage and trading infrastructure firm that offers services such as liquidity provision and over-the-counter options, while 21Shares has product‐management expertise in issuing ETPs that track the value of underlying crypto assets.

The acquisition provides FalconX with an instant foundation in terms of getting its foot in the door for regulated investment vehicles instead of having to build them from scratch. With a bigger platform, the combined company could accelerate product launch, offer more crypto-backed products globally, and possibly attract larger institutional clients.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23